dexmedetomidine has been researched along with Kidney Failure in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y; Wang, C; Yu, Y; Zhang, J | 1 |
| Chen, CY; Chen, YT; Fu, MX; Jian, YP; Li, SX; Li, XD; Li, Y; Li, YQ; Liu, DH; Ma, J; Mo, ZW; Ning, DS; Ou, JS; Ou, ZJ; Peng, YM; Xu, KQ; Yuan, HX | 1 |
2 other study(ies) available for dexmedetomidine and Kidney Failure
| Article | Year |
|---|---|
The therapeutic effect of dexmedetomidine on protection from renal failure via inhibiting KDM5A in lipopolysaccharide-induced sepsis of mice.
Topics: Acute Kidney Injury; Adrenergic alpha-2 Receptor Agonists; Animals; Cytokines; Dexmedetomidine; Kidney; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Protective Agents; Renal Insufficiency; Retinoblastoma-Binding Protein 2; Sepsis; Signal Transduction; Tumor Necrosis Factor-alpha | 2019 |
Circulating extracellular vesicles from patients with valvular heart disease induce neutrophil chemotaxis via FOXO3a and the inhibiting role of dexmedetomidine.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Animals; Case-Control Studies; Chemokine CCL5; Chemotaxis, Leukocyte; Dexmedetomidine; Extracellular Vesicles; Female; Forkhead Box Protein O3; Heart Valve Diseases; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Kidney; Male; Mice; Middle Aged; Neutrophils; Phosphorylation; Platelet Factor 4; Proto-Oncogene Proteins c-akt; Renal Insufficiency; Vasodilation | 2020 |